The current panel of genes with strong evidence for use in clinical practice include PALB2, CHEK2, ATM, RAD51C and RAD51D with additional genes such as BARD1 (breast cancer) and BRIP1 (ovarian cancer) continuing to emerge. Here, RAD51C is linked to ovarian cancer.